Skip to main content

Advertisement

SpringerLink
Log in

Issues with Fertility in Young Women with Breast Cancer

  • Breast Cancer (B Overmoyer, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

There are competing risks and benefits of cancer therapies and fertility preservation in young women with breast cancer. Here we discuss the impact of therapy on fertility, fertility preservation options, and emerging information in fertility issues for the breast cancer patient.

Recent Findings

All systemic forms of breast cancer treatment can impact future fertility. Pre-therapy fertility preservation may offer the best opportunity for future fertility. Shared decision making with the individual patient and clinical scenario is important. Early referral to a fertility specialist should be offered to young patients.

Summary

We find that fertility preservation options for young women diagnosed with breast cancer are currently available, but potentially under-utilized. We conclude that a multidisciplinary approach is necessary, with discussion of potential risks and benefits of fertility preservation options in the context of the patient’s clinical disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Hery C, Ferlay J, Boniol M, Autier P. Changes in breast cancer incidence and mortality in middle-aged and elderly women in 28 countries with Caucasian majority populations. Ann Oncol. 2008;19(5):1009–18. https://doi.org/10.1093/annonc/mdm593.

    Article  CAS  PubMed  Google Scholar 

  2. Merlo DF, Ceppi M, Filiberti R, et al. Breast cancer incidence trends in European women aged 20–39 years at diagnosis. Breast Cancer Res Treat. 2012;134(1):363–70. https://doi.org/10.1007/s10549-012-2031-7.

    Article  CAS  PubMed  Google Scholar 

  3. Anders CK, Johnson R, Litton J, Phillips M, Bleyer A. Breast cancer before age 40 years. Semin Oncol. 2009;36(3):237–49. https://doi.org/10.1053/j.seminoncol.2009.03.001.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, et al. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat. 2009;113(2):357–70. https://doi.org/10.1007/s10549-008-9926-3.

    Article  PubMed  Google Scholar 

  5. Kollias J, Elston CW, Ellis IO, Robertson JF, Blamey RW. Early-onset breast cancer--histopathological and prognostic considerations. Br J Cancer. 1997;75(9):1318–23. http://www.ncbi.nlm.nih.gov/pubmed/9155052. Accessed 30 Jan 2019.

    Article  CAS  Google Scholar 

  6. Gnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N, Margenthaler JA. Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. J Am Coll Surg. 2009;208(3):341–7. https://doi.org/10.1016/j.jamcollsurg.2008.12.001.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Chen H, Zhou M, Tian W, Meng K, He H. Effect of Age on Breast Cancer Patient Prognoses: A Population-Based Study Using the SEER 18 Database. Coleman WB, ed. PLoS One. 2016;11(10):e0165409. doi:https://doi.org/10.1371/journal.pone.0165409.

    Article  Google Scholar 

  8. Meirow D, Schiff E. Appraisal of chemotherapy effects on reproductive outcome according to animal studies and clinical data. J Natl Cancer Inst Monogr. 2005;2005(34):21–5. https://doi.org/10.1093/jncimonographs/lgi025.

    Article  CAS  Google Scholar 

  9. Maltaris T, Boehm D, Dittrich R, Seufert R, Koelbl H. Reproduction beyond cancer: A message of hope for young women 2006. doi:https://doi.org/10.1016/j.ygyno.2006.08.003.

    Article  Google Scholar 

  10. NCCN. Pregnancy after cancer. https://www.nccn.org/patients/resources/life_after_cancer/pregnancy.aspx. Accessed 17 Feb 2019.

  11. Pagani O, Ruggeri M, Manunta S, Saunders C, Peccatori F, Cardoso F, et al. Pregnancy after breast cancer: are young patients willing to participate in clinical studies? Breast. 2015;24(3):201–7. https://doi.org/10.1016/j.breast.2015.01.005.

    Article  PubMed  Google Scholar 

  12. Henry NL, Xia R, Schott AF, McConnell D, Banerjee M, Hayes DF. Prediction of postchemotherapy ovarian function using markers of ovarian reserve. Oncologist. 2014;19(1):68–74. https://doi.org/10.1634/theoncologist.2013-0145.

    Article  CAS  PubMed  Google Scholar 

  13. Rossi L, Pagani O. Impact of breast cancer treatment on fertility. In: Breast Cancer, fertility preservation and reproduction. Cham: Springer International Publishing; 2015. p. 29–43. https://doi.org/10.1007/978-3-319-17278-1_3.

    Chapter  Google Scholar 

  14. Jung M, Shin HJ, Rha SY, Jeung HC, Hong S, Moon YW, et al. The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with long-term follow-up. Ann Surg Oncol. 2010;17(12):3259–68. https://doi.org/10.1245/s10434-010-1172-3.

    Article  PubMed  Google Scholar 

  15. Oktem O, Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer. 2007;110(10):2222–9. https://doi.org/10.1002/cncr.23071.

    Article  CAS  PubMed  Google Scholar 

  16. Morgan S, Anderson RA, Gourley C, Wallace WH, Spears N. How do chemotherapeutic agents damage the ovary? Hum Reprod Update. 2012;18(5):525–35. https://doi.org/10.1093/humupd/dms022.

    Article  CAS  PubMed  Google Scholar 

  17. Minton SE, Munster PN. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control. 2002;9(6):466–72. https://doi.org/10.1177/107327480200900603.

    Article  PubMed  Google Scholar 

  18. Fornier MN, Modi S, Panageas KS, Norton L, Hudis C. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer. 2005;104(8):1575–9. https://doi.org/10.1002/cncr.21385.

    Article  CAS  PubMed  Google Scholar 

  19. Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update. 7(6):535–43. http://www.ncbi.nlm.nih.gov/pubmed/11727861. Accessed 30 Jan 2019.

    Article  CAS  Google Scholar 

  20. •• Zhao J, Liu J, Chen K, et al. What lies behind chemotherapy-induced amenorrhea for breast cancer patients: a meta-analysis. Breast Cancer Res Treat. 2014;145(1):113–28. https://doi.org/10.1007/s10549-014-2914-x. A recent meta-analysis on the impact of multiple types of chemotherapy on chemotherapy-induced amenorrhea. Review and synthesis of available data.

    Article  CAS  PubMed  Google Scholar 

  21. Zagouri F, Sergentanis TN, Chrysikos D, Papadimitriou CA, Dimopoulos M-A, Bartsch R. Trastuzumab administration during pregnancy: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013;137(2):349–57. https://doi.org/10.1007/s10549-012-2368-y.

    Article  CAS  PubMed  Google Scholar 

  22. Rosenberg SM, Partridge AH. Management of breast cancer in very young women. Breast. 2015;24:S154–8. https://doi.org/10.1016/j.breast.2015.07.036.

    Article  PubMed  Google Scholar 

  23. Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol. 2014;32(21):2255–69. https://doi.org/10.1200/JCO.2013.54.2258.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805–16. https://doi.org/10.1016/S0140-6736(12)61963-1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Gray RG, Rea D, Handley K, et al. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol. 2013;31(18_suppl):5. https://doi.org/10.1200/jco.2013.31.18_suppl.5.

    Article  Google Scholar 

  26. Braems G, Denys H, De Wever O, Cocquyt V, Van den Broecke R. Use of tamoxifen before and during pregnancy. Oncologist. 2011;16(11):1547–51. https://doi.org/10.1634/theoncologist.2011-0121.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, et al. Adjuvant ovarian suppression in premenopausal breast Cancer. N Engl J Med. 2015;372(5):436–46. https://doi.org/10.1056/NEJMoa1412379.

    Article  CAS  PubMed  Google Scholar 

  28. •• Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;379(2):122–37. https://doi.org/10.1056/NEJMoa1803164. Long-term follow-up of the SOFT and TEXT trials, demonstrating ovarian suppression with tamoxifen is superior to tamoxifen alone, and exemestane with ovarian suppression is superior to tamoxifen with ovarian suppression.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, et al. Adjuvant Exemestane with ovarian suppression in premenopausal breast Cancer. N Engl J Med. 2014;371(2):107–18. https://doi.org/10.1056/NEJMoa1404037.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. •• Saha P, Regan MM, Pagani O, et al. Treatment efficacy, adherence, and quality of life among women younger than 35 years in the International Breast Cancer Study Group TEXT and SOFT adjuvant endocrine therapy trials. J Clin Oncol. 2017;35(27):3113–22. https://doi.org/10.1200/JCO.2016.72.0946. Young (age < 35 years) premenopausal women with ER+ cancers experience similar symptoms to tamoxifen and ovarian suppression to older women. Approximately 20% of these premenopausal patients stop recommended therapy because of symptoms.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Rosenberg SM, Gelber S, Gelber RD, Krop E, Korde LA, Pagani O, et al. Oncology physicians’ perspectives on practices and barriers to fertility preservation and the feasibility of a prospective study of pregnancy after breast cancer. J Adolesc Young Adult Oncol. 2017;6(3):429–34. https://doi.org/10.1089/jayao.2017.0031.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Lambertini M, Ceppi M, Poggio F, et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol. 2015;26(12):mdv374. https://doi.org/10.1093/annonc/mdv374.

    Article  Google Scholar 

  33. Armstrong DK, Ω C, Plaxe SC, et al. NCCN Guidelines Version 2.2018 Ovarian Cancer Continue.; 2019. www.nccn.org/patients. Accessed 30 Jan 2019.

  34. Stroud JS, Mutch D, Rader J, Powell M, Thaker PH, Grigsby PW. Effects of cancer treatment on ovarian function. Fertil Steril. 2009;92(2):417–27. https://doi.org/10.1016/j.fertnstert.2008.07.1714.

    Article  CAS  PubMed  Google Scholar 

  35. Peate M, Meiser B, Friedlander M, Zorbas H, Rovelli S, Sansom-Daly U, et al. It’s now or never: fertility-related knowledge, decision-making preferences, and treatment intentions in young women with breast cancer--an Australian fertility decision aid collaborative group study. J Clin Oncol. 2011;29(13):1670–7. https://doi.org/10.1200/JCO.2010.31.2462.

    Article  PubMed  Google Scholar 

  36. Jukkala AM, Azuero A, McNees P, Bates GW, Meneses K. Self-assessed knowledge of treatment and fertility preservation in young women with breast cancer. Fertil Steril. 2010;94(6):2396–8. https://doi.org/10.1016/j.fertnstert.2010.03.043.

    Article  PubMed  Google Scholar 

  37. Partridge AH, Gelber S, Peppercorn J, Sampson E, Knudsen K, Laufer M, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004;22(20):4174–83. https://doi.org/10.1200/JCO.2004.01.159.

    Article  PubMed  Google Scholar 

  38. Baynosa J, Westphal LM, Madrigrano A, Wapnir I. Timing of breast cancer treatments with oocyte retrieval and embryo cryopreservation. J Am Coll Surg. 2009;209(5):603–7. https://doi.org/10.1016/j.jamcollsurg.2009.08.006.

    Article  PubMed  Google Scholar 

  39. Goldfarb SB, Kamer SA, Oppong BA, Eaton A, Patil S, Junqueira MJ, et al. Fertility preservation for the young breast cancer patient. Ann Surg Oncol. 2016;23(5):1530–6. https://doi.org/10.1245/s10434-015-5036-8.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Anderson RA, Cameron DA. Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab. 2011;96(5):1336–43. https://doi.org/10.1210/jc.2010-2582.

    Article  CAS  PubMed  Google Scholar 

  41. Ruddy KJ, O’Neill A, Miller KD, Schneider BP, Baker E, Sparano JA, et al. Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103. Breast Cancer Res Treat. 2014;144(3):591–7. https://doi.org/10.1007/s10549-014-2891-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Scheffer GJ, Broekmans FJM, Looman CWN, Blankenstein M, Fauser BC, teJong F, et al. The number of antral follicles in normal women with proven fertility is the best reflection of reproductive age. Hum Reprod. 2003;18(4):700–6. http://www.ncbi.nlm.nih.gov/pubmed/12660259. Accessed 30 Jan 2019.

    Article  CAS  Google Scholar 

  43. Kasum M, Šimunić V, Orešković S, Beketić-Orešković L. Fertility preservation with ovarian stimulation protocols prior to cancer treatment. Gynecol Endocrinol. 2014;30(3):182–6. https://doi.org/10.3109/09513590.2013.860123.

    Article  CAS  PubMed  Google Scholar 

  44. Revelli A, Salvagno F, Casano S, Piane LD, Benedetto C. Fertility preservation, ART, and breast cancer. In: Breast cancer, fertility preservation and reproduction. Cham: Springer International Publishing; 2015. p. 45–59. https://doi.org/10.1007/978-3-319-17278-1_4.

    Chapter  Google Scholar 

  45. Reddy J, Oktay K. Ovarian stimulation and fertility preservation with the use of aromatase inhibitors in women with breast cancer. Fertil Steril. 2012;98(6):1363–9. https://doi.org/10.1016/j.fertnstert.2012.09.022.

    Article  CAS  PubMed  Google Scholar 

  46. Rodriguez-Wallberg KA, Oktay K. Fertility preservation in women with breast cancer. Clin Obstet Gynecol. 2010;53(4):753–62. https://doi.org/10.1097/GRF.0b013e3181f96e00.

    Article  PubMed  PubMed Central  Google Scholar 

  47. •• Rodriguez-Wallberg KA, Eloranta S, Krawiec K, Lissmats A, Bergh J, Liljegren A. Safety of fertility preservation in breast cancer patients in a register-based matched cohort study. Breast Cancer Res Treat. 2018;167(3):761–9. https://doi.org/10.1007/s10549-017-4555-3. A cohort/registry study that identifies fertility preservation protocols with hormone stimulation are not associated with worse oncologic outcomes compared to fertility preservation without hormone stimulation.

    Article  PubMed  Google Scholar 

  48. •• Rodgers RJ, Reid GD, Koch J, et al. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review. Hum Reprod. 2017;32(5):1033–45. https://doi.org/10.1093/humrep/dex027. A meta-analysis of the literature which did not find differences in disease-specific recurrence and survival for patients undergoing ovarian hyperstimulation compared to those who did not for fertility preservation.

    Article  CAS  PubMed  Google Scholar 

  49. Lee S, Ozkavukcu S, Heytens E, Moy F, Oktay K. Value of early referral to fertility preservation in young women with breast cancer. J Clin Oncol. 2010;28(31):4683–6. https://doi.org/10.1200/JCO.2010.30.5748.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Rodriguez-Wallberg KA, Oktay K. Fertility preservation and pregnancy in women with and without BRCA mutation–positive breast cancer. Oncologist. 2012;17(11):1409–17. https://doi.org/10.1634/theoncologist.2012-0236.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. van Tilborg TC, Broekmans FJ, Pijpe A, Schrijver LH, Mooij TM, Oosterwijk JC, et al. Do BRCA1/2 mutation carriers have an earlier onset of natural menopause? Menopause. 2016;23(8):903–10. https://doi.org/10.1097/GME.0000000000000633.

    Article  PubMed  Google Scholar 

  52. •• Derks-Smeets IAP, de Die-Smulders CEM, Mackens S, et al. Hereditary breast and ovarian cancer and reproduction: an observational study on the suitability of preimplantation genetic diagnosis for both asymptomatic carriers and breast cancer survivors. Breast Cancer Res Treat. 2014;145(3):673–81. https://doi.org/10.1007/s10549-014-2951-5. An observational study on the effectiveness of pre-implantation genetic diagnosis for a cohort of BRCA mutation carriers, and results of successful pregnancies.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY, 10065, USA

    Nicole Christian & Mary L. Gemignani

Authors
  1. Nicole Christian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mary L. Gemignani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mary L. Gemignani.

Ethics declarations

Conflict of Interest

Nicole Christian and Mary L. Gemignani declare they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Breast Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Christian, N., Gemignani, M.L. Issues with Fertility in Young Women with Breast Cancer. Curr Oncol Rep 21, 58 (2019). https://doi.org/10.1007/s11912-019-0812-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11912-019-0812-4

Keywords

Search

Navigation